American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Rosen
    Rosen
  3. Hudis
    Hudis
  4. Scher
    Scher
  5. Norton
    Norton
  6. Berger
    Berger
  7. Ladanyi
    Ladanyi
  8. Chandarlapaty
    Chandarlapaty
  9. Kris
    Kris
  10. Schultz
    Schultz

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1045)
  4. Breast Medicine Service (611)
  5. Human Oncology and Pathogenesis Program (529)
  6. Genitourinary Oncology Service (528)
  7. Sloan Kettering Institute Postdocs (479)
  8. Department of Pathology and Laboratory Medicine (441)
  9. Sloan Kettering Institute Faculty (441)
  10. Hematologic Malignancies, Division of (438)
Search Within
  1. "Department of Medicine"
Formats
  1. Meeting Abstract (1077)
  2. Journal Article (996)
  3. Editorial (34)
  4. Review (21)
  5. Conference Paper (3)
  6. Correspondence (3)
  7. Miscellaneous (3)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1045)
  4. Breast Medicine Service (611)
  5. Human Oncology and Pathogenesis Program (529)
  6. Genitourinary Oncology Service (528)

More Groups

People
  1. David Solit (176)
  2. Neal Rosen (142)
  3. Clifford Hudis (141)
  4. Howard Scher (139)
  5. Larry Norton (110)
  6. Michael Berger (106)

More People

Years
  1. 2025 (29)
  2. 2024 (55)
  3. 2023 (59)
  4. 2022 (172)
  5. 2021 (174)
  6. 2020 (188)

More Years

Publications
  1. Cancer Research (1239)
  2. Clinical Cancer Research (899)

Results (2138)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RIT1 drives oncogenic transformation and is an actionable target in lung adenocarcinoma
    Journal Article

    Mozzarelli, A. M.; Cuevas-Navarro, A.; Shuldiner, E. G.; Vega, M.; Chatila, W. K.; Xu, J.; Walch, H. S.; Niu, Y. Z.; Petrov, D. A.; Schultz, N.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • Identifying triple-negative breast cancer patients at high risk of worse prognosis using molecular features derived from histology images
    Meeting Abstract

    Oh, J. H.; Pareja, F.; Elkin, R.; Norton, L.; Deasy, J.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Multimodal AI modeling of clinical panel-based sequencing for HRD detection in ovarian cancer
    Meeting Abstract

    Alsaafin, A.; Pollard, T.; Aukerman, A. T.; Boehm, K.; Pasha, A.; Moore, D.; Rusk, N.; Begum, A.; Sullivan, M. W.; Graves, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Improving global access to genomic profiling in rare pediatric cancers
    Journal Article

    Sait, S. F.; O’Donohue, T. J.; Bale, T.; Bowman, A.; Hill, K.; Stockfisch, E.; Giantini-Larsen, A.; Alano, T.; Rosenblum, M.; Benhamida, J.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Clinicopathologic features, molecular landscape, and prognostic implications of ovarian low-grade serous tumors with histologic transformation
    Journal Article

    Chui, M. H.; Kang, E. Y.; Kahn, R. M.; Chiang, S.; Zhou, Q.; Iasonos, A.; Manning-Geist, B.; Selenica, P.; Da Cruz Paula, A.; Long Roche, K.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • ctDNA analysis in ERBB2-amplified colorectal cancer: Biomarker analysis of the MyPathway trial
    Journal Article

    Meric-Bernstam, F.; Raghav, K. P. S.; Sweeney, C. J.; Swanton, C.; Spigel, D. R.; Bose, R.; Burris, H. A.; Friedman, C. F.; Espenschied, C. R.; Grindheim, J. M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase I study of FHD-286, a dual BRG1/BRM (SMARCA4/SMARCA2) inhibitor, in patients with advanced myeloid malignancies
    Journal Article

    DiNardo, C. D.; Fathi, A. T.; Kishtagari, A.; Bhalla, K. N.; Quintás-Cardama, A.; Reilly, S. A.; Almon, C.; Patriquin, C.; Nabhan, S.; Healy, K.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
    Journal Article

    Tap, W. D.; Cote, G. M.; Burris, H.; Gore, L.; Elias, A.; Beeram, M.; Conley, A. P.; Gianolio, D. A.; Qu, Z.; Pandya, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Longitudinal genomic analysis to fine-tune targeted therapy: Results of the phase II LOGIC 2 trial in patients with BRAF(V600)-mutant metastatic melanoma
    Journal Article

    Dummer, R.; Sandhu, S.; Miller, W. H. Jr; Butler, M. O.; Taylor, M. H.; Heinzerling, L.; Blank, C. U.; Muñoz-Couselo, E.; Burris, H. A. 3rd; Postow, M. A.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant plus abemaciclib in hormone receptor–positive advanced or recurrent endometrial cancer
    Journal Article

    Green, A. K.; Zhou, Q.; Iasonos, A.; Zammarrelli, W. A. 3rd; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Loh, J.; Hom, V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: